Business article - April 15, 2021
Throwback Thursday: Eugen Steiner – The company doctor
Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap – a family of venture capital funds investing globally in life sciences] is like a company doctor. I deliver […]
Prio - June 11, 2020
Pharma industry confronts growing problem of pharmaceutical waste
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health. While pharmaceutical companies are stepping up their efforts to tackle the issue, watchdog organizations, the UN, the […]
Profiles in Business - December 1, 2019
Eugen Steiner: The company doctor
Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap – a family of venture capital funds investing globally in life sciences] is like a company doctor. I deliver […]
Prio - June 18, 2019
Pharma industry confronts growing problem of pharmaceutical waste
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health.
Profiles in Science - March 7, 2019
Donna Strickland: “It’s all about the science”
Science has always been a driving force in Donna Strickland's life. From the moment she discovered the world of laser physics, she’s been entranced by all the possibilities lasers represent for research, science and medicine.
Biotech article - January 1, 2013
Risky Business
Biotech is an industry with great promise — and great risk. Reaping the benefits of a promising new drug while sidestepping the quicksand of expensive, super-sized failures is no easy feat. In recent years, with a string of high-profile, late-stage drug failures, many venture capitalists jumped ship for safer waters. No one understands this better […]